Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...

Shares of Dr. Reddy's Laboratories Ltd. will be closely watched in Wednesday's trading as its revenue for the September ...

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.

Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.

Analysts this morning are spotlighting varied stock trends, with Citi maintaining a cautious stance on Dr. Reddy’s ...

Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...

Despite reporting decent earnings for the July-September quarter, brokerages continue to maintain their neutral stance over ...

Dr Reddy’s Laboratories posted a mixed performance in Q2FY25, reporting record revenue of Rs 8,038.2 crore, marking a strong ...

With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...

New Delhi: Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net ...

Stocks including Titan Company, Dr Reddy's Labs, NTPC, Tata Steel, Infosys, GAIL (India), Hero Motocorp, Mankind Pharma and ...

Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended September 30 ...